Igm Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Glazer Capital, LLC and Paul J. Glazer report a complete divestment of their beneficial ownership in IGM Biosciences, Inc. as of September 30, 2025.
Glazer Capital, LLC and its managing member, Paul J. Glazer, have disclosed a passive beneficial ownership of 7.3% in IGM Biosciences, Inc.'s common stock.
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 10.5% beneficial ownership stake in IGM Biosciences Inc. as of December 31, 2024.
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.2% in IGM Biosciences Inc.'s common stock as of January 31, 2025.